These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34915346)

  • 41. Design of a gene family screening library targeting G-protein coupled receptors.
    Lamb ML; Bradley EK; Beaton G; Bondy SS; Castellino AJ; Gibbons PA; Suto MJ; Grootenhuis PD
    J Mol Graph Model; 2004 Sep; 23(1):15-21. PubMed ID: 15331050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands.
    Weill N; Rognan D
    J Chem Inf Model; 2009 Apr; 49(4):1049-62. PubMed ID: 19301874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
    Bissantz C; Bernard P; Hibert M; Rognan D
    Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
    Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
    J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemical Diversity in the G Protein-Coupled Receptor Superfamily.
    Vass M; Kooistra AJ; Yang D; Stevens RC; Wang MW; de Graaf C
    Trends Pharmacol Sci; 2018 May; 39(5):494-512. PubMed ID: 29576399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ligand-Based Pharmacophore Modeling Using Novel 3D Pharmacophore Signatures.
    Kutlushina A; Khakimova A; Madzhidov T; Polishchuk P
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30486389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A simple open source bioinformatic methodology for initial exploration of GPCR ligands' agonistic/antagonistic properties.
    Panagiotopoulos AA; Papachristofi C; Kalyvianaki K; Malamos P; Theodoropoulos PA; Notas G; Calogeropoulou T; Castanas E; Kampa M
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00600. PubMed ID: 32662237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists.
    Bernard D; Coop A; MacKerell AD
    J Am Chem Soc; 2003 Mar; 125(10):3101-7. PubMed ID: 12617677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors.
    Emtage AL; Mistry SN; Fischer PM; Kellam B; Laughton CA
    J Biomol Struct Dyn; 2017 Sep; 35(12):2604-2619. PubMed ID: 27532213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective pharmacophore design for alpha1-adrenoceptor subtypes.
    MacDougall IJ; Griffith R
    J Mol Graph Model; 2006 Sep; 25(1):146-57. PubMed ID: 16406718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacophore modeling and parallel screening for PPAR ligands.
    Markt P; Schuster D; Kirchmair J; Laggner C; Langer T
    J Comput Aided Mol Des; 2007; 21(10-11):575-90. PubMed ID: 17960326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multi-Pharmacophore Modeling of Caspase-3 Inhibitors using Crystal, Dock and Flexible Conformation Schemes.
    Kumar SP; Jha PC
    Comb Chem High Throughput Screen; 2018; 21(1):26-40. PubMed ID: 29295689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists.
    Sirci F; Goracci L; Rodríguez D; van Muijlwijk-Koezen J; Gutiérrez-de-Terán H; Mannhold R
    J Comput Aided Mol Des; 2012 Nov; 26(11):1247-66. PubMed ID: 23065321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
    Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
    PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. G protein-coupled receptors--recent advances.
    Latek D; Modzelewska A; Trzaskowski B; Palczewski K; Filipek S
    Acta Biochim Pol; 2012; 59(4):515-29. PubMed ID: 23251911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential application of ligand and structure based modeling approaches to index chemicals for their hH4R antagonism.
    Pappalardo M; Shachaf N; Basile L; Milardi D; Zeidan M; Raiyn J; Guccione S; Rayan A
    PLoS One; 2014; 9(10):e109340. PubMed ID: 25330207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Template selection and refinement considerations for modelling aminergic GPCR-ligand complexes.
    Urmi KF; Finch AM; Griffith R
    J Mol Graph Model; 2017 Sep; 76():488-503. PubMed ID: 28818718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).
    Jacobson KA
    Bioconjug Chem; 2009 Oct; 20(10):1816-35. PubMed ID: 19405524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
    Southern C; Cook JM; Neetoo-Isseljee Z; Taylor DL; Kettleborough CA; Merritt A; Bassoni DL; Raab WJ; Quinn E; Wehrman TS; Davenport AP; Brown AJ; Green A; Wigglesworth MJ; Rees S
    J Biomol Screen; 2013 Jun; 18(5):599-609. PubMed ID: 23396314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.